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Cardiac radiation dose distribution, cardiac events and mortality
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Background: The impact of radiation dose to the heart in early-stage lung cancer patients treated with
definitive stereotactic body radiation therapy (SBRT) is not well known. We, therefore, analyzed whether
higher radiation dose to the heart would lead to an increase in cardiac toxicity and overall mortality.
Methods: Seventy-four patients with 75 tumors treated definitively with SBRT for early-stage non-small
cell lung cancer (NSCLC) and two cases of limited-stage small cell lung cancer (SCLC) with an average
follow-up of 35 months (range, 1–130 months) were retrospectively analyzed. The whole heart and cardiac
substructures including atria, ventricles, heart valves, atrioventricular (AV) node and four major coronary
artery branches were contoured using commercial treatment planning software. For each structure, multiple
dose-volume parameters were recorded. The relation between radiation doses to the heart, tumor location,
and preexisting medical conditions with the development of cardiac events and mortality was assessed.
Results: Overall, there was large variability in dose to cardiac substructures: mean heart dose (MHD)
averaged 1.90 Gy (range, 0.04–11.00 Gy) equivalent 2 Gy dose (EQD2) and average max dose to the left
anterior descending artery (LAD) was 5.67 Gy (range, 0.04–48.60 Gy) EQD2. Patients with tumor location
in the upper lobes received higher cardiac radiation dose compared to other lobes (P<0.0001). There was no
difference in MHD between central and peripheral tumor locations. The distance between heart and tumor
was negatively associated with MHD (r=−0.61, P<0.0001). Eighteen patients developed cardiac complications
including the need for defibrillator placement, arrhythmia development and worsening heart failure.
Preexisting cardiac disease was associated with an increased number of cardiac events after radiotherapy
(P=0.039). However, neither radiation dose to the whole heart or the cardiac substructures, nor comorbidities
such as diabetes, hypercholesterolemia, hypertension or COPD were associated with the number of cardiac
events or overall mortality.
Conclusions: Radiation doses to the heart and its substructures show large variability. Cardiac events
occurred more frequently in patients with a history of heart problems. At present, the effect of radiation dose
on cardiac toxicity is unclear in patients undergoing SBRT for early-stage lung cancer. Longer follow-up and
a larger cohort are needed to assess for late cardiac sequelae.
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Introduction
Radiation dose to the heart has been associated with
cardiovascular mortality and cardiac complications
predominantly in long term survivors with breast cancer (1-3),
Hodgkin’s lymphoma (4) and pediatric malignancies (5).
Cardiac toxicity appears to be dependent on the radiation
dose and radiation technique (1,6,7). Radiation therapy dose
to various cardiac substructures has been associated with
coronary artery, pericardial, and conduction system diseases
as well as cardiomyopathy (8). For breast cancer, the
radiation dose distribution to various heart regions has been
well-described (9). In addition, a recent study demonstrated
a clinically-relevant dose-effect relationship between mean
heart dose (MHD), left ventricle volume receiving 5 Gy and
acute coronary events (6).
Recently, interest in cardiac toxicity in lung cancer patients
has increased (10). Several studies showed that radiation dose
to the heart in stage III lung cancer patients was associated
with the development of cardiac events (7,11-15) and overall
survival (12,14,15). Importantly, RTOG 0617 showed
that the heart volume receiving ≥5 and 30 Gy predicted
overall survival. While cardiac toxicity is usually a late
event, cardiotoxicity has also been observed early after
radiotherapy (11). Because of this, it is important to
investigate earlier time points in addition to the late ones.
Cardiotoxicity in patients treated with SBRT for early-stage
lung cancer delivering higher doses per fraction to smaller
subvolumes depending on the individual tumor location has
not been studied in great detail. In this setting, patients who
are inoperable or who choose not to undergo surgery are
treated with radiation therapy. Patients with early-stage lung
cancer have a better prognosis than locally-advanced lung
cancer patients (16) and thus are more likely to survive to
experience cardiac toxicity. Still, despite good locoregional
tumor control and a moderate prevalence of distant
metastases, 5-year survival rates of 41.2% are surprisingly
low indicating that factors other than tumor contribute to
high mortality rates (17). Two retrospective studies recently
investigated cardiac dose as a predictor of mortality in
early-stage lung cancer stereotactic body radiation therapy
(SBRT). While one study found no relation between
mean dose for the whole heart and survival (18), the other,
larger study observed that radiotherapy doses mainly to
the upper regions of the heart were associated with noncancer death (19). Our study aims to provide a more
detailed analysis than what is currently available on cardiac
dose and patient outcomes after SBRT. We investigate in
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particular the association of radiation therapy doses to the
heart and its multiple substructures with cardiac events and
overall survival. In addition, we also analyze the influence
of preexisting cardiac disease and other comorbidities with
respect to the development of cardiac events and survival.
Methods
Aim, design and setting
Seventy-four patients with 75 tumors treated definitively
with SBRT for stage I or II non-small cell lung cancer
(NSCLC) (72 cases) and small cell lung cancer (SCLC)
(2 cases) at our institution were retrospectively analyzed
on an IRB-approved protocol (VCU IRB HM15356).
Information was gathered from electronic medical records.
Following radiotherapy, patients returned for regular
follow-up visits that included clinical history, physical exam
and computed tomography imaging every 3 months for the
first 2 years, then every 6 months up to 5 years, and yearly
afterwards. Patients were seen by cardiologists as clinically
indicated. All available medical records from all specialties
were utilized for this study. The relation between radiation
doses to the heart and cardiac substructures, tumor location,
and preexisting medical conditions with the development of
cardiac events and mortality was assessed. Any new cardiac
conditions that occurred after radiotherapy were recorded
as cardiac events. These included diseases of the cardiac
conduction system, structural heart disease, heart failure
and ischemic cardiac disease.
Patient characteristics
Patients were treated definitively with lung SBRT
between 2007 and 2017. All of these patients were medical
inoperable or refused surgery. Chemotherapy or surgery
were not utilized. Seventy-seven percent of patients
received 48 Gy in 4 fractions. Other doses ranged from
40 Gy in 4 fractions to 60 Gy in 8 fractions. The average
follow-up was 35 months, median was 27 months, ranging
from 1 month to 10 years and 10 months. Sixty-one (82%)
of patients were treated for newly diagnosed lung cancer
and 13 (18%) were treated for lung cancer recurrence. All
recurrences were treated initially with surgery except for
three cases which were treated with radiochemotherapy. All
patients who underwent thoracic radiation therapy prior to
SBRT of lung cancer had negligible heart doses. Details of
patient characteristics including preexisting cardiac disease
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Table 1 Patient clinical characteristics at baseline (N=74)
Characteristic

Table 2 Radiation therapy parameters

No. of patients

%

Male

36

49

Female

38

51

Age, years

Mean: 70 (range, 48–91)

BMI (body mass index)

Mean: 26 (range, 14–44)

Parameter

Mean

Range

Total radiation dose (Gy)

49

40–60

Dose per fraction (Gy)

11

5–20

Number of fractions used

4

3–10

Gender

Prior cardiac history
Yes

42

57

No

32

43

Current

28

38

Quit

44

59

Never

1

1

Unknown

1

1

Smoking

Smoking pack years

Mean: 49 (range, 0–240)

Diabetes mellitus
Yes

19

26

No

54

73

Unknown

1

1

Hypertension
Yes

64

86

No

9

12

Unknown

1

1

Yes

38

51

No

35

47

Unknown

1

1

Adenocarcinoma

28

39

Squamous cell
carcinoma

25

35

Other

8

11

Unknown

11

15

Upper right and left

42

57

Lower right and left and
middle

32

43

Central tumor

38

51

Peripheral tumor

36

49

Hypercholesterolemia

Subtype

Tumor lobe

Tumor location
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No. of
%
patients

48 Gy in 4 fractions

57

77

Other fractionations

17

23

Static beams (3DCRT or IMRT)

31

42

VMAT

43

58

Technique

GTV (cc)

18

2–70

PTV (cc)

44

7–170

Distance PTV to heart (cm)

3.5

−0.9 to 6

3DCRT, 3-dimensional conformal radiotherapy; IMRT, intensitymodulated radiation therapy; VMAT, volumetric modulated arc
radiotherapy; GTV, gross tumor volume; PTV, planning target
volume.

and comorbidities are described in Table 1. Note that all
patients with hyperlipidemia, diabetes and hypertension
were included in the studies whether the diseases were
medically controlled or not.
Further treatment information is listed in Table 2 and
details of cardiac conditions are listed in Table 3. Patients
were included in this analysis if they had a tumor located
within 6 cm of the heart border, as larger distances resulted
in minimal (<0.1 Gy) radiation exposure of the heart.
The distance was recorded as the smallest distance in cm
between the planning target volume (PTV) and heart
border. If there was overlap between PTV and heart, then
a negative distance was recorded. Central tumor location
was defined as being within 2 cm of the mediastinum and
central airways.
Dosimetric parameters
The whole heart and cardiac substructures (13 substructures
including 2 atria, 2 ventricles, 4 heart valves, AV node and
four major coronary artery branches) were contoured on
the 30% phase of the 4D treatment planning CT of each
patient using commercial treatment planning software
Pinnacle (Philips, The Netherlands) and MIM 6.6.10
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M

M

M

F

F

F

M

M

M

M

M

M

F

M

F

F

F

F

62

58

67

83

74

85

67

58

59

61

54

64

74

66

58

73

72

57

6

32

18

4

3

17

22

22

6

3

23

60

6

9

33

20

41

12

Time to first
event (mo)

CAD s/p stent, cardiac arrhythmia

None

MI s/p CABG, CAD

CAD, MI s/p CABG, tricuspid valve
repair, systolic CHF

Prior cardiac morbidity

None

Systolic CHF stage C, A Fib

Moderate aortic stenosis

SVT with elevated troponin due to
demand ischemia with severe LVH

Pacemaker placement

Lupus, severe COPD

Severe COPD, pulmonary fibrosis,
PVD, pulmonary hypertension

None

COPD

COPD, asthma

Diastolic heart failure, 4 cardiac stents, Prolonged hospital stays,
paroxysmal SVT
intraabdominal abscesses, small
bowel obstruction

None

COPD, CKD stage V

CHF, rheumatic mitral regurgitation s/p h/o PE, severe COPD
repair, multivessel CAD s/p CABG

Hospitalized due to worsening CHF CAD, MI, CHF

Mitral valve replacement, CHF

Hospitalized due to worsening CHF A Fib, CAD s/p CABG, mitral valve
replacement, CHF

Diastolic CHF exacerbations, 3
NSTEMI s/p 5 stents

COPD

Severe COPD, bladder carcinoma
s/p cystectomy

Carotid stenosis, peripheral
vascular disease

COPD, peripheral vascular disease

Sarcoidosis, severe COPD

COPD, right carotid
endarterectomy

H/o T2 N2 SCC LUL s/p
chemoradiation to 59.6 Gy
13.5 years prior, COPD

Severe COPD

Peripheral vascular disease

Other comorbidities

A fib, pericardial disease, diastolic CHF COPD, ESRD

CAD

None

Left ventricular systolic dysfunction None

A Flutter w/ RVR s/p cardioversion
and radiofrequency ablation

NSTEMI

NSTEMI

A Fib with RVR

Hospitalized with paroxysmal A Fib CAD

Hospitalized with an arrhythmia

PCI for CAD, right ventricular failure, CAD s/p CABG
pulmonary hypertension

E.D. visit for tachycardia

E.D. visit for A Fib

MI s/p catheterization

ICD implantation and CHF

Event details

47.56

37.69

65.14

33.19

4.63

5.91

17.79

5.83

18.99

15.43

15.41

28.14

20.59

2.04

70.26

12.94

15.28

5.52

92.02

71.1

135.88

63.79

11.9

22.05

49.89

23.21

57.92

42.69

44.97

71.67

55.73

7.19

112.03

28.24

33.72

12.94

GTV (cc) PTV (cc)

0.07

0.44

7.50

0.17

1.98

2.28

5.69

0.47

1.03

3.80

1.32

1.49

0.12

0.09

1.94

0.05

9.05

0.10

MHD (EQD2
in Gy)

ICD, implantable cardioverter-defibrillator; CHF, congestive heart failure; E.D., emergency department; CAD, coronary artery disease; CABG, coronary artery bypass
grafting, s/p, status post; A Fib, atrial fibrillation; h/o, history of; SCC, squamous cell carcinoma; LUL, left upper lobe; NOS, not otherwise specified; PCI, percutaneous
coronary intervention; L, liters; O2, oxygen; RVR, rapid ventricular response; NSTEMI, non-ST segment elevation MI; A Flutter, atrial flutter; ESRD, end-stage renal disease;
PVD, peripheral vascular disease; PE, pulmonary embolism, CKD, chronic kidney disease; SVT, supraventricular tachycardia; LVH, left ventricular hypertrophy.

Sex

Age

Table 3 Patients with symptomatic cardiac events
Journal of Thoracic Disease, Vol 10, No 4 April 2018
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(Cleveland, OH, USA) according to contouring atlas
guidelines (20). For each structure, dose-volume parameters
including mean dose, highest dose to 0.03 cm3 (D0.03cc) and
percentage of a given structure receiving either ≥5, 10, 20,
30, 40, 50 or 60 Gy (V5-Gy, V10-Gy …) were recorded. D0.03cc
was used in accordance with AAPM TG 101 guidelines for
SBRT (21). Equivalent doses of 2-Gy fractions (EQD2)
were calculated from the dose-volume histograms as
nd[(d+α/β)÷(2+α/β)], where n was the number of fractions,
d was the dose to the structure per fraction (in Gy), and
α/β was 2 Gy (22). For the patient with two tumors treated
at the same time, the composite treatment plan was used
to calculate the total dose to the heart structures from both
treatments.
Statistical analysis
Mann-Whitney U test was used to test significance of
differences in cardiac radiation dose for tumor location,
treatment technique, cardiac toxicity, and overall and noncancer survival as well as the difference in survival and
cardiotoxicity in patients based on the number of smoking
pack years. Pearson correlation coefficient was used to
assess the relationship between tumor distance and PTV
size with heart radiation dose. Chi-squared distribution and
Kaplan-Meier estimator were calculated to determine the
relationship between prior cardiac events, diabetes mellitus,
hypertension, hypercholesterolemia and cardiotoxicity
development and overall survival. All tests were done with a
significance level of P<0.05.
Results
Dosimetry
Radiation dose distributions to various cardiac substructures
are described in Table 4. All reported doses are expressed
in Gy EQD2. There was considerable variability in dose
to different cardiac substructures: MHD averaged 1.90 Gy
(range, 0.04–11.0 Gy) and average D 0.03cc to the left
anterior descending artery (LAD) was 5.67 Gy (range
0.04-48.8 Gy). Figure 1A,B,C,D illustrates some of the
important dose distributions. Notably, MHD >2 Gy was
found in 23 patients and MHD >5 Gy was observed in
8 patients. Ten patients received a D 0.03cc of 60 Gy or
more. Patients with tumors in the upper lobes received
higher MHD and heart D0.03cc compared to the other lobes
(3.31 Gy versus 1.15 Gy, P<0.0001 and 41.06 Gy versus

© Journal of Thoracic Disease. All rights reserved.

29.51 Gy, P=0.00034). We did not observe a significant
difference in MHD or heart D0.03cc between central and
peripheral location of the tumors (P=0.84 and P=0.27).
The distance between heart and tumor was weakly
associated with the MHD (r=−0.61 and P≤0.0001). The
magnitude of PTV was only weakly associated with MHD
(r=0.41, P=0.0004). Static beams (3DCRT or IMRT)
radiation technique did not significantly differ from
VMAT for MHD or Heart D 0.03cc (P=0.61 and P=0.95).
RTOG 0813 constraints (Heart/Pericardium <15 cc max
dose is 32 Gy and maximum point dose is 105% of PTV
prescription) (23) were met by all patients except for four
cases. Of these, only one developed a cardiac event (heart
attack) after radiation treatment. In addition, no patient
with a distance of >5 cm between PTV edge and heart in
this cohort had a MHD >5 Gy.
Mortality
At the time of analysis, 28 patients had died (38%), 20 of
non-cancer related deaths (one of them of heart failure) and
8 of cancer progression. 38 were alive (51%), 8 were lost to
follow-up. Kaplan-Meier estimated 1-year overall survival
was 96%, and 2-year survival was 77%. Prior cardiac
disease, radiation dose to the whole heart or the cardiac
substructures, number of pack years smoked, diabetes,
COPD, hypercholesterolemia and hypertension were not
associated with overall mortality (Figure 2A).
Cardiac events
18 patients developed cardiac events after on average
19 months (range, 3–60 months). The cohorts that
developed cardiac events and those that did not, had
comparable demographics. The most common events were
arrhythmia development (8 cases), coronary artery disease
(7 cases), congestive heart failure (5 cases) and one case of
mitral valve replacement (in addition to a worsening heart
failure). Details of cardiac events are listed in Table 3. While
arrhythmias occurred on average at 26 months, coronary
artery disease and heart failure occurred on average at
15 and 13 months, respectively. Prior cardiac disease was
associated with an increased rate of cardiac events after
radiotherapy (14 of 42 patients with prior cardiac history
developed cardiac events compared to 4 out of 32 patients
with no prior history of cardiac events (odds ratio =3.5,
P=0.039). Cardiac event-free survival was associated with
prior cardiac disease (P=0.075, Figure 2B). Radiation dose
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Table 4 Radiation dose to cardiac substructures (all values are
EQD2)
Substructure

Mean (Gy) Median (Gy)

Range (Gy)

Table 4 (continued)
Substructure

Mean (Gy) Median (Gy)

Range (Gy)

Right coronary artery

Whole heart
Mean dose

1.90

1.03

0.04–11.00

D0.03cc

33.38

13.10

0.15–212.22

Mean dose

2.27

0.64

0.02–17.47

D0.03cc

5.53

2.55

0.03–47.91

Mean dose

1.46

0.51

0.02–9.71

D0.03cc

12.87

5.96

0.07–194.45

Mean dose

2.02

0.16

0.02–15.04

D0.03CC

2.58

0.18

0.04–18.63

Right ventricle

Aortic valve
Mean dose

2.21

0.47

0.05–10.37

D0.03cc

4.04

0.74

0.07–33.47

Tricuspid valve

AV node
Mean dose

1.93

0.18

0–15.19

D0.03cc

2.73

0.20

0.01–20.63

cc, cubic centimeters, D 0.03cc (Gy), minimum radiation dose
received by the highest dose 0.03 cc volume of a given structure
expressed in Gy.

Left anterior descending
artery
Mean dose

2.01

0.80

0.02–16.17

D0.03cc

5.67

2.30

0.04–48.60

Mean dose

3.38

1.62

0.06–43.47

D0.03cc

20.67

9.19

0.13–195.20

Mean dose

3.65

0.53

0.02–35.52

D0.03cc

5.59

0.80

0.04–64.73

Mean dose

3.03

0.51

0.05–32.73

D0.03cc

4.06

0.73

0.05–34.38

Mean dose

1.47

0.20

0.02–12.02

D0.03cc

12.92

2.84

0.09–143.68

Mean dose

2.39

0.18

0.01–22.79

D0.03cc

3.09

0.20

0.02–28.80

Mean dose

2.85

0.54

0.04–33.26

D0.03cc

5.61

1.22

0.06–45.72

Mean dose

3.03

0.52

0.03–31.38

D0.03cc

21.37

5.76

0.07–211.47

Left atrium

Left circumflex artery

Left main coronary artery

Left ventricle

Mitral valve

Pulmonic valve

Right atrium

Table 4 (continued)

© Journal of Thoracic Disease. All rights reserved.

to the whole heart or the cardiac substructures, number of
pack years smoked, diabetes, COPD, hypercholesterolemia
and hypertension was not associated with cardiac events
after radiotherapy. Figure 3 illustrates that radiation dose
distribution is similar between patients who experienced
cardiac events and those who did not (P=0.68).
Discussion
In this study, we investigated the impact of radiation
dose to cardiac substructures and the whole heart and the
development of cardiac events in early-stage lung cancer
treated with SBRT. There is evidence that radiation
dose to certain structures of the heart contributes to the
development of cardiac toxicity (6,15,24). However, our
analysis did not find statistically significant correlations
between radiation dose to the total heart or its substructures
and overall survival or development of cardiac events. We
observed that doses to the heart and its substructures
show large variability among patients. As expected,
there was an inverse correlation of radiation dose with
the distance of the tumor from the heart, although this
correlation was weak. Radiotherapy to centrally-located
or large tumors did not necessarily result in higher
cardiac dose compared to peripherally-located and
smaller tumors. Furthermore, more advanced radiation
treatment technology did not necessarily spare the
heart from excessive radiation dose. While in our study
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B

Mean heart dose

Heart D0.03cc

70

70

60

60

50

50

Frequency

Frequency

A

40
30

40
30

20

20

10

10

0

0
0

2

4

6

8

10

12

0

50

100

D

Left ventricle V5Gy

200

250

50

60

LAD D0.03cc

70

70

60

60

50

50

Frequency

Frequency

C

150

Gy EQD2

Gy EQD2

40
30

40
30

20

20

10

10

0

0
0

20

40

60

80

100

0

% of volume receiving 5 Gy

10

20

30

40

Gy EQD2

Figure 1 Examples for radiation dose distribution. (A) Mean heart dose distribution in Gy (EQD2); (B) heart D0.03cc dose distribution in Gy
(EQD2); (C) frequencies at which left ventricle received ≥5 Gy (EQD2); (D) left anterior descending artery (LAD) D0.03cc dose distribution
in Gy (EQD2).

patients with preexisting cardiac conditions were more
likely to develop cardiac events, patients with other
medical comorbidities were not. These findings will add
to the understanding of cardiac events following SBRT
in early-stage lung cancer.
Radiotherapy-induced cardiac toxicity
In breast, lymphoma and locally-advanced lung cancer,
standard fractionation is typically utilized as opposed to
SBRT which is studied here (2-4,7). High doses with SBRT
only involve a small volume of the heart. For tumors located
close to the heart, the dose to a small area can be fairly high.

© Journal of Thoracic Disease. All rights reserved.

Because of this, exploring the dose to individual cardiac
substructures is important (6,9). Indeed, it is currently
unknown how much radiation dose is safe to administer
to the heart under these circumstances (25). Higher
radiation doses to the left ventricle (6), LAD (25) and left
atrium (15) have been associated with an increased rate of
post-radiotherapy cardiac events which is mainly postulated
to be due to ischemic changes. Pericardial disease,
conduction system disorders and cardiomyopathy have
been identified as radiotherapy-induced cardiotoxicities
as well, though to a lesser extent (8). If a substructure that
is particularly sensitive to radiation therapy is identified,
SBRT technique can be used to create a dose distribution
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A

1.0
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B

0.8

Survival probability

1.0

Cardiac toxicity-free survival

Prior cardiac events
No prior cardiac events

0.6

0.4

0.2

Prior cardiac events
No prior cardiac events

0.8

0.6

0.4

0.2

P=0.075

P=0.95
0.0

0.0
0

20

40

60

80

100

120

0

Time to death (months)

Number at risk
Years:
0
Prior cardiac events:
38
No prior cardiac events: 28

2
25
15

4
15
5

6
4
3

8
0
1

20

40

80

100

120

Time to death (months)

Number at risk
Years:
0
Prior cardiac events:
42
No prior cardiac events: 32

10
0
1

60

2
21
15

4
10
5

6
1
3

8
0
1

10
0
1

Figure 2 Kaplan-Meier Curves. (A) Overall survival; (B) cardiac toxicity-free survival among patients with and without prior heart disease.

14

40

13

38

12
30

Frequency

Frequency

10
8
6
4

20

9

10

2
1

2

1

6

1

2

0
0

0

2

4

6

8

10

0
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Figure 3 Radiation dose distribution in patients with and without prior cardiac events. P value for difference in mean heart dose =0.68.

that avoids specific substructures as much as possible (11,25).
Cardiac toxicity following SBRT has rarely been
reported. Only two other studies investigated radiation dose
to the heart in early stage lung cancer treated with SBRT.
The follow-up times in those studies were comparable to
our report (18,19). Tembhekar et al. show results similar to
ours. Cardiac dose was not associated with overall survival
in lung cancer SBRT (18). The dose-volume parameters
of the heart in this study are comparable to ours (MHD
1.57 Gy compared to 2.26 Gy in ours and maximum
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heart dose 14.07 Gy compared to 15.64 Gy in ours).
The second much larger study including 803 patients by
Stam et al. showed that maximum dose to the left atrium
and the dose to 90% of the superior vena cava were
significantly associated with non-cancer death (19). The
pathophysiologic mechanism behind this observation is
not clear (26). The dose-volume parameters of the heart
in this report are considerably different from ours [MHD
was 11.40 Gy (EQD2) compared to 1.90 Gy (EQD2) in
ours and left atrium maximum dose was 6.50 Gy (EQD2)
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compared to 3.38 Gy (EQD2) in ours], while tumor sizes
were similar. Stam et al. did not investigate any association
with cardiac events. The causative relation of high doses
with cardiac events and cardiac mortality is therefore still
unclear. However, the present study provides more detailed
analysis on cardiac dose and patient outcomes after SBRT
in early-stage lung cancer. Interestingly, in our cohort no
pericardial effusions were observed, which is commonly
observed after radiotherapy for locally advanced lung
cancer (14).

hypertension, smoking status and the development of
cardiac events. In addition, longer follow-up times might be
needed to fully characterize cardiac events after SBRT. For
locally advanced lung cancer, post-radiation therapy cardiac
events occurred at a median of 26 months after therapy, but
happened as early as one month (7), whereas in our study
cardiac events were observed after on average 19 months
(3–60 months). Therefore, even with rather short follow-up
times of 35 months on average , early cardiac events can be
identified.

Preexisting cardiac conditions

Limitations

Five-year overall survival for early-stage lung cancer
patients treated with SBRT is only 44% which underscores
the relevance of non-cancer contributors to mortality (17).
At 30 days, cardiovascular disease has been reported as
the most frequent cause of death in early-stage NSCLC
patients (23). In our study, patients with preexisting cardiac
conditions were more likely to develop cardiac events
after radiation therapy. Notably, in our patient population
various comorbidities were more common than in most
patients who are treated for early-stage lung cancer.
Therefore most of the patients in our cohort were medical
inoperable. While the association between cardiac eventfree survival and preexisting heart conditions did not reach
statistical significance—likely due to insufficient patient
numbers—there was a clear separation of the Kaplan-Meier
curves (Figure 2B). Thus, the relation between cardiac dose
and radiotherapy-related heart toxicity remains unclear
and further clinical studies are needed to determine how
much care should be taken to avoid delivering potentially
detrimental radiotherapy doses to the heart and its
substructures. This includes assessment of interfraction
variations of dose delivery to the heart (24). Our findings
indicate that patients with preexisting heart conditions need
to be observed with great care as they are at a higher risk
for cardiac events which might or might not be related to
SBRT.

Similar to the other two studies on SBRT and cardiac
toxicity (18,19), ours is also limited by its retrospective
nature. Further investigations are needed to determine
whether radiation dose to the heart or individual
substructures lead to the development of cardiotoxicity
and mortality in early-stage lung cancer. Longer followup, larger patient samples, prospective study design and
contouring of individual cardiac substructures are essential.
Echocardiography, coronary computed tomography
and angiography may be helpful to predict which
patients are likely to develop cardiac events early after
treatment (26). Radiation-induced cardiac disease was
reported to be associated with marked thickening, fibrosis
and narrowing of coronary arteries (28) and by radiationinduced perfusion defects (29). However, these studies were
done using standard fractionation radiotherapy and not
SBRT. Learning more about the mechanism of radiationinduced heart damage may lead to the development
of cardioprotective medications, such as possibly ROS
scavengers, and to the discovery of biomarkers for
cardiotoxicity (26,30).

Other medical comorbidities
There is evidence that medical comorbidities, particularly
COPD, play a role in lung cancer mortality (23,27).
However, the role of comorbidities in early-stage lung
cancer treated with radiation therapy is a relatively
unexplored area. In our cohort, we did not identify any
association between diabetes, high cholesterol, COPD,

© Journal of Thoracic Disease. All rights reserved.

Conclusions
Doses to the heart and its substructures show large
variability and depend on the tumor location in earlystage lung cancer. New cardiac events after SBRT were
associated with patients’ history of heart problems. Lung
cancer patients with preexisting heart conditions need to
be watched closely as heart disease might affect morbidity
and potentially influence survival. Longer follow-up times
and greater patient samples may be needed to identify
correlations between comorbidities, radiation technique
or cardiac radiation doses with cardiac events or overall
survival.
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